ANI Pharmaceuticals, Inc.

NasdaqGM:ANIP Stock Report

Market Cap: US$2.0b

ANI Pharmaceuticals Future Growth

Future criteria checks 4/6

ANI Pharmaceuticals is forecast to grow earnings and revenue by 41.8% and 7.8% per annum respectively. EPS is expected to grow by 43.2% per annum. Return on equity is forecast to be 23.5% in 3 years.

Key information

41.8%

Earnings growth rate

43.19%

EPS growth rate

Pharmaceuticals earnings growth12.5%
Revenue growth rate7.8%
Future return on equity23.47%
Analyst coverage

Good

Last updated05 Sep 2025

Recent future growth updates

Recent updates

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Aug 10
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Surges 25% Yet Its Low P/S Is No Reason For Excitement

ANI Pharmaceuticals: Classic Case Of Capital Intensive Growth Hampering Value

Jul 28

Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?

Jun 21
Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?

We Think Shareholders Will Probably Be Generous With ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) CEO Compensation

May 16
We Think Shareholders Will Probably Be Generous With ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) CEO Compensation

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Fly 25% But Investors Aren't Buying For Growth

Mar 28
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Fly 25% But Investors Aren't Buying For Growth

Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?

Feb 25
Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?

ANI Pharmaceuticals: More Than Just A Generics Company

Feb 11

ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Prospects Need A Boost To Lift Shares

Dec 18
ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Prospects Need A Boost To Lift Shares

Here's Why ANI Pharmaceuticals (NASDAQ:ANIP) Can Manage Its Debt Responsibly

Nov 09
Here's Why ANI Pharmaceuticals (NASDAQ:ANIP) Can Manage Its Debt Responsibly

ANI Pharmaceuticals Is Acting Like It Is Being Acquired

Nov 02

ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market

Oct 11
User avatar

Purified Cortrophin Gel And Strategic Acquisitions Propel Robust Revenue Surge In Rare Disease Sector

Accelerating demand for their lead Rare Disease asset and growth in generics, along with expanding sales efforts, are expected to significantly boost revenues.

There's No Escaping ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Muted Revenues

Sep 10
There's No Escaping ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Muted Revenues

ANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Weaker Than They Seem

Aug 14
ANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Weaker Than They Seem

Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?

Aug 08
Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?

ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028

Aug 02

Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price

Jun 10
Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price

ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked

Jun 10

These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well

Feb 17
These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well

Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings

Nov 15
Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings

Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

Sep 22
Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

Earnings and Revenue Growth Forecasts

NasdaqGM:ANIP - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20271,007792112286
12/31/2026919471731998
12/31/2025839421591788
6/30/2025747-13104139N/A
3/31/2025674-224981N/A
12/31/2024614-204764N/A
9/30/2024555-107493N/A
6/30/20245392394113N/A
3/31/20245173195116N/A
12/31/202348715100119N/A
9/30/2023449105370N/A
6/30/2023401-81941N/A
3/31/2023359-28-79N/A
12/31/2022316-50-48-31N/A
9/30/2022283-69-53-39N/A
6/30/2022251-65-52-48N/A
3/31/2022226-63-61-36N/A
12/31/2021216-43-203N/A
9/30/2021212-22-1610N/A
6/30/2021213-17-1714N/A
3/31/2021213-152334N/A
12/31/2020208-23-5315N/A
9/30/2020199-24-4226N/A
6/30/2020198-20-1549N/A
3/31/2020203-1-3233N/A
12/31/201920761846N/A
9/30/2019216164168N/A
6/30/2019215172855N/A
3/31/201920814N/A58N/A
12/31/201820215N/A67N/A
9/30/20181920N/A56N/A
6/30/20181890N/A64N/A
3/31/20181870N/A56N/A
12/31/2017177-1N/A39N/A
9/30/20171687N/A36N/A
6/30/20171585N/A20N/A
3/31/20171454N/A23N/A
12/31/20161294N/A27N/A
9/30/20161088N/A20N/A
6/30/20169010N/A29N/A
3/31/20167812N/A27N/A
12/31/20157615N/A17N/A
9/30/20157933N/A23N/A
6/30/20157735N/A17N/A
3/31/20156430N/A18N/A
12/31/20145629N/A22N/A
9/30/20144511N/A8N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ANIP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.1%).

Earnings vs Market: ANIP is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ANIP is expected to become profitable in the next 3 years.

Revenue vs Market: ANIP's revenue (7.8% per year) is forecast to grow slower than the US market (9.6% per year).

High Growth Revenue: ANIP's revenue (7.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ANIP's Return on Equity is forecast to be high in 3 years time (23.5%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/09/15 18:23
End of Day Share Price 2025/09/15 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ANI Pharmaceuticals, Inc. is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dewey SteadmanCanaccord Genuity
Timothy ChiangCapital One Securities, Inc.
Dana FlandersGuggenheim Securities, LLC